Keeps Biopharma Inc.

KOSDAQ:A256940 Stock Report

Market Cap: ₩121.7b

Keeps Biopharma Past Earnings Performance

Past criteria checks 0/6

Keeps Biopharma has been growing earnings at an average annual rate of 29.9%, while the Semiconductor industry saw earnings growing at 2.1% annually. Revenues have been growing at an average rate of 53.6% per year.

Key information

29.89%

Earnings growth rate

32.10%

EPS growth rate

Semiconductor Industry Growth23.50%
Revenue growth rate53.64%
Return on equity-3.81%
Net Margin-1.26%
Last Earnings Update31 Mar 2026

Recent past performance updates

Analysis Article • Mar 31

KPS (KOSDAQ:256940) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Despite posting some strong earnings, the market for KPS Corporation's ( KOSDAQ:256940 ) stock hasn't moved much. We...

Recent updates

Analysis Article • Jan 06

Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Dec 01

Keeps Biopharma Inc.'s (KOSDAQ:256940) Shares Not Telling The Full Story

There wouldn't be many who think Keeps Biopharma Inc.'s ( KOSDAQ:256940 ) price-to-sales (or "P/S") ratio of 1.3x is...
Analysis Article • Sep 06

Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Aug 01

Not Many Are Piling Into Keeps Biopharma Inc. (KOSDAQ:256940) Stock Yet As It Plummets 27%

Keeps Biopharma Inc. ( KOSDAQ:256940 ) shares have retraced a considerable 27% in the last month, reversing a fair...
Analysis Article • Jun 17

Market Participants Recognise Keeps Biopharma Inc.'s (KOSDAQ:256940) Revenues Pushing Shares 43% Higher

Keeps Biopharma Inc. ( KOSDAQ:256940 ) shares have continued their recent momentum with a 43% gain in the last month...
Analysis Article • May 15

Is Keeps Biopharma (KOSDAQ:256940) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Apr 18

Further Upside For Keeps Biopharma Inc. (KOSDAQ:256940) Shares Could Introduce Price Risks After 33% Bounce

Keeps Biopharma Inc. ( KOSDAQ:256940 ) shares have continued their recent momentum with a 33% gain in the last month...
Analysis Article • Feb 06

A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) 33% Share Price Climb

The KPS Corporation ( KOSDAQ:256940 ) share price has done very well over the last month, posting an excellent gain of...
Analysis Article • Jan 13

KPS (KOSDAQ:256940) Takes On Some Risk With Its Use Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Dec 06

A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) Share Price

There wouldn't be many who think KPS Corporation's ( KOSDAQ:256940 ) price-to-sales (or "P/S") ratio of 0.7x is worth a...
Analysis Article • Mar 31

KPS (KOSDAQ:256940) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Despite posting some strong earnings, the market for KPS Corporation's ( KOSDAQ:256940 ) stock hasn't moved much. We...
Analysis Article • Feb 26

Sentiment Still Eluding KPS Corporation (KOSDAQ:256940)

With a median price-to-sales (or "P/S") ratio of close to 1.8x in the Semiconductor industry in Korea, you could be...

Revenue & Expenses Breakdown

How Keeps Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A256940 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 26188,936-2,38231,6052,591
31 Dec 25170,147-9,78529,8172,591
30 Sep 25157,755-2826,9471,051
30 Jun 25148,356-1,24122,447837
31 Mar 25136,521-7,28815,560610
31 Dec 24127,5831,1138,570801
30 Sep 24125,7636,8857,320875
30 Jun 24118,5178,3246,6621,072
31 Mar 24113,33512,3857,2241,242
31 Dec 2392,1333,9307,3721,450
30 Sep 2365,750-10,8789,8701,584
30 Jun 2347,685-10,7069,3471,627
31 Mar 2323,939-11,2358,7101,661
31 Dec 2214,617-11,3757,2892,164
30 Sep 2212,256-12,3547,9683,208
30 Jun 226,852-13,9717,7993,494
31 Mar 224,997-15,6328,1343,425
31 Dec 214,261-15,3178,4012,810
30 Sep 215,888-6,3434,1601,593
30 Jun 2111,440-7,1124,1991,028
31 Mar 2111,345-5,0303,365874
31 Dec 2015,217-2,4063,172830
30 Sep 2012,719-3,6713,333801
30 Jun 208,331-1,1623,068839
31 Mar 2010,004-5453,458834
31 Dec 1914,191-3463,444780
30 Sep 1929,3143,9734,262785
30 Jun 1944,0837,1565,204725
31 Mar 1946,4738,1085,027631
31 Dec 1840,6286,8074,953604
30 Sep 1829,1983,3344,653557
30 Jun 1817,1942274,336515
31 Dec 1724,0432,1934,318355

Quality Earnings: A256940 is currently unprofitable.

Growing Profit Margin: A256940 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A256940 is unprofitable, but has reduced losses over the past 5 years at a rate of 29.9% per year.

Accelerating Growth: Unable to compare A256940's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A256940 is unprofitable, making it difficult to compare its past year earnings growth to the Semiconductor industry (27.4%).

Return on Equity

High ROE: A256940 has a negative Return on Equity (-3.81%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/17 08:18
End of Day Share Price 2026/07/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Keeps Biopharma Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
YoungSik YoonShinhan Investment Corp.
Sun-Jae HeoSK Securities Co., Ltd.